Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Ocean Biomedical (OCEA) Competitors

OCEA vs. ANIX, CTMX, ADAG, ASRT, ME, ANL, KPTI, GNLX, ALXO, and PMVP

Should you be buying Ocean Biomedical stock or one of its competitors? The main competitors of Ocean Biomedical include Anixa Biosciences (ANIX), CytomX Therapeutics (CTMX), Adagene (ADAG), Assertio (ASRT), 23andMe (ME), Adlai Nortye (ANL), Karyopharm Therapeutics (KPTI), Genelux (GNLX), ALX Oncology (ALXO), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical preparations" industry.

Ocean Biomedical vs.

Anixa Biosciences (NASDAQ:ANIX) and Ocean Biomedical (NASDAQ:OCEA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Anixa Biosciences' average media sentiment score of 1.92 beat Ocean Biomedical's score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Anixa Biosciences Very Positive
Ocean Biomedical Neutral

Anixa Biosciences has higher revenue and earnings than Ocean Biomedical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anixa Biosciences$210K412.20-$9.81M-$0.39-6.90
Ocean BiomedicalN/AN/A-$114.47MN/AN/A

Ocean Biomedical's return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Anixa BiosciencesN/A -54.79% -50.37%
Ocean Biomedical N/A N/A N/A

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 24.6% of Ocean Biomedical shares are owned by institutional investors. 22.6% of Anixa Biosciences shares are owned by insiders. Comparatively, 73.5% of Ocean Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Anixa Biosciences has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Ocean Biomedical has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Anixa Biosciences presently has a consensus price target of $8.50, suggesting a potential upside of 215.99%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than Ocean Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anixa Biosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Ocean Biomedical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Anixa Biosciences received 20 more outperform votes than Ocean Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ocean Biomedical an outperform vote while only 70.59% of users gave Anixa Biosciences an outperform vote.

CompanyUnderperformOutperform
Anixa BiosciencesOutperform Votes
24
70.59%
Underperform Votes
10
29.41%
Ocean BiomedicalOutperform Votes
4
100.00%
Underperform Votes
No Votes

Summary

Anixa Biosciences beats Ocean Biomedical on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCEA vs. The Competition

MetricOcean BiomedicalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$23.12M$6.57B$5.14B$9.08B
Dividend YieldN/A2.99%5.09%4.23%
P/E RatioN/A10.5989.9717.17
Price / SalesN/A196.061,116.34117.09
Price / CashN/A57.1643.1037.85
Price / Book-0.255.094.784.78
Net Income-$114.47M$151.83M$120.31M$225.60M

Ocean Biomedical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCEA
Ocean Biomedical
N/A$0.66
+12.8%
N/A+11.4%$23.12MN/A0.00N/AGap Down
High Trading Volume
ANIX
Anixa Biosciences
2.9493 of 5 stars
$2.80
-1.8%
$8.50
+203.6%
-29.0%$90.10M$210,000.00-7.315
CTMX
CytomX Therapeutics
4.3314 of 5 stars
$1.15
+3.6%
$5.77
+402.0%
-22.7%$90.00M$101.21M6.53170News Coverage
Positive News
ADAG
Adagene
2.0015 of 5 stars
$2.03
-1.5%
$5.00
+146.3%
+18.5%$89.87M$815,746.000.00260
ASRT
Assertio
3.3746 of 5 stars
$0.94
+2.2%
$3.25
+245.7%
-18.7%$89.75M$125.76M-1.3020Gap Down
ME
23andMe
1.9347 of 5 stars
$3.34
-0.3%
$9.40
+181.4%
-80.8%$87.24M$219.64M-0.13770
ANL
Adlai Nortye
1.5754 of 5 stars
$2.36
+3.1%
$9.00
+281.4%
-75.5%$87.08M$5M0.00127Positive News
Gap Up
KPTI
Karyopharm Therapeutics
3.8097 of 5 stars
$0.67
-4.3%
$5.00
+646.3%
-16.5%$84.55M$148.44M-0.61380
GNLX
Genelux
0.8813 of 5 stars
$2.36
+1.3%
$18.25
+673.3%
-83.8%$81.51M$8,000.00-2.4510
ALXO
ALX Oncology
3.3412 of 5 stars
$1.54
+6.2%
$10.67
+592.6%
-87.6%$81.22MN/A-0.5440Analyst Forecast
News Coverage
PMVP
PMV Pharmaceuticals
1.7884 of 5 stars
$1.56
-1.3%
$5.80
+271.8%
-45.8%$80.73MN/A0.0050

Related Companies and Tools


This page (NASDAQ:OCEA) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners